Functional Impact of a Closed-loop Controlled Grasping Neuroprosthesis in Post-stroke Patients (PREHENSTROKE)
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · May 9, 2019
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient must have given free and informed consent and signed the consent;
- • The patient must be an affiliate or a beneficiary of a health insurance plan;
- • The patient is hospitalized as part of routine care and available for at least 3 consecutive days of follow-up during hospitalization;
- • Motor deficiency of the upper limb due to a hemorrhagic or ischemic stroke;
- • Stroke more than one months old;
- • Inability to perform an active extension of the long fingers (opening of the hand) to voluntarily seize an empty glass with a palmar grip (grasping task in the ARAT scale), while the subject can hold the previously placed glass passively in the hand; and / or
- • Inability to perform an active thumb extension to voluntarily grasp the handle of a tablespoon (flat, like a key) with a pulpo-lateral thumb-index or key-grip (grasping task in the Wolf Motor Function Scale Test), while the subject can hold the spoon previously placed passively between thumb and index;
- • Ability to sit on a chair for at least 2 hours.
- Exclusion Criteria:
- • The subject participates in another interventional study;
- • The subject is in an exclusion period determined by a previous study;
- • The subject is under the protection of justice, guardianship or curatorship;
- • The subject refuses to sign or give consent;
- • It is not possible to give the subject enlightened information.
- • The patient is pregnant, parturient, or breastfeeding;
- • Patient with pacemaker;
- • Unstable epilepsy;
- • Unstable cardiovascular pathology (coronary heart disease, major hypertension, heart failure);
- • Dermatological problems counter-indicating the application of surface electrodes;
- • Musculotendinous retractions or joint stiffness of the fingers and wrist preventing passive opening of the hand sufficient to perform the functional tasks evaluated;
- • Active elbow extension limited to not reaching the ipsilateral knee, the subject sitting (limitation of the approach);
- • Upper limb pain limiting movements;
- • Major sensory disorders corresponding to a score of the Modified Erasmus Nottingham Sensory Assessment English version of the upper limb \<10/44;
- • Severe aphasia with aphasia severity scale of the Boston Diagnostic Severity Aphasia Examination \<= 3, indicating that there may be a clear decrease in verbal fluency or ease and speed of understanding, with no significant limitation expression or communication;
- • Unilateral spatial negligence highlighted with the bell test if the difference between omissions in the left and right fields is greater than or equal to 6;
- • Common extensor digitorum muscle and / or extensor thumb muscle non-stimulable with the neuroprosthesis.
About Centre Hospitalier Universitaire De Nīmes
The Centre Hospitalier Universitaire de Nîmes (CHU Nîmes) is a leading academic medical center located in Nîmes, France, dedicated to advancing healthcare through innovative clinical research and patient care. As a prominent sponsor of clinical trials, CHU Nîmes collaborates with a multidisciplinary team of healthcare professionals and researchers to conduct rigorous studies aimed at improving treatment outcomes and enhancing medical knowledge across various specialties. With a strong commitment to ethical standards and patient safety, CHU Nîmes fosters a research environment that encourages scientific excellence and contributes to the development of new therapies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nîmes, , France
Nîmes, , France
Toulouse, , France
Patients applied
Trial Officials
Christine Azevedo, PhD
Study Chair
Institut National de Recherche en Informatique et en Automatique
Jérôme Froger, MD
Principal Investigator
Centre Hospitalier Universitaire de Nīmes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials